|
|
Yang Y, Chen X, zhang Z, Lin L. Comparative analysis of radiation therapy outcomes in breast cancer patients with and without prior chemotherapy. Int J Radiat Res 2025; 23 (3) :613-618 URL: http://ijrr.com/article-1-6580-en.html
Department of General Surgery, Fourth Affiliated Hospital of Harbin Medical University, Harbin City, Heilongjiang Province, China , llq12351@163.com
Abstract: (575 Views)
Background: Chemotherapy is often prescribed for breast cancer treatment; however, how it affects disease-free survival, quality of life, and recurrence rates remains inadequately defined. This study aims at investigating relationships between chemotherapy and disease-free survival, quality of life, and recurrence percentages among breast cancer patients. Materials and Methods: This was a retrospective chart review of 350 breast cancer patients who underwent surgery between 2015 and 2022 at a university medical center. The participants received treatment such that the target group consisted of those receiving chemotherapy (n=105) and those not receiving chemotherapy (n=245). Comparison of demographic data such as tumor characteristics and treatment details between the two study groups will be carried out. Cox proportional hazards models as well as multivariate analysis of variance (MANOVA) and logistic regression will be used to evaluate disease-free survival, quality of life, and recurrence. Follow up assessment was done at 12 months. Results: Chemotherapy patients were significantly less likely to experience disease recurrence than those not exposed to Chemotherapy (HR=0.65, p=0.02) or local recurrence (OR=0.42, p=0.01). Patients who had chemotherapy again had lower physical and social functioning scores compared with those who were not given chemotherapy (p=0.04 and p=0.02, respectively). Chemotherapy was associated with an increased 12-month survival probability (92.5% vs 85.1%, p=0.03). Conclusion: Chemotherapy has an association with improved disease-free survival and decreased local recurrence in breast cancer patients, but it also adversely affects life quality, particularly specific aspects such as physical and social functions. These results emphasize that balance between benefit of treatment and quality of life should be carefully considered in treatment of breast cancer and that further investigations must occur for optimizing chemotherapy usage.
References
1. StatPearls Publishing LLC. (2024). Breast cancer. Retrieved from: https://www.ncbi.nlm.nih.gov/books/NBK482435 2. Suo S, Liu R, Yu X, Wang J, Wang M, Zhang Y, et al. (2024) Incidence and risk factors of pain following breast cancer surgery: a retrospec tive national inpatient sample database study. BMC Womens Health, 24(1): 583. [ DOI:10.1186/s12905-024-03430-3] 3. Biskup M, Macek P, Zak M, Krol H, Terek-Derszniak M, Gozdz S (2024) Influence of obesity and sociodemographic features on the physical fitness of breast cancer survivors. Geriatrics (Basel), 9(5): 125. [ DOI:10.3390/geriatrics9050125] 4. Wuerstlein R, Harbeck N (2017) Neoadjuvant therapy for HER2-positive breast cancer. Rev Recent Clin Trials, 12(2): 81-92. [ DOI:10.2174/1574887112666170202165049] 5. Schwartz G (2005) Surgical issues in patients with breast cancer receiv ing neoadjuvant chemotherapy. Minerva Ginecologica, 57(3): 327-348. 6. Goble S and Bear HD (2003) Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the ques tions. Surg Clin North Am, 83(4): 943-971. [ DOI:10.1016/S0039-6109(03)00071-9] 7. Steenbruggen TG, van Ramshorst MS, Kok M, Linn SC, Smorenburg CH, Sonke GS (2017) Neoadjuvant therapy for breast cancer: established concepts and emerging strategies. Drugs, 77(12):1313-1336. [ DOI:10.1007/s40265-017-0774-5] 8. Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst, 97(3): 188-194. [ DOI:10.1093/jnci/dji021] 9. Peintinger F, Kuerer HM, McGuire SE, Bassett R, Pusztai L, Symmans WF (2008) Residual specimen cellularity after neoadjuvant chemo therapy for breast cancer. Br J Surg, 95(4): 433-437. [ DOI:10.1002/bjs.6044] 10. Ghasemi F and Brackstone M (2024) The impact of neoadjuvant versus adjuvant chemotherapy on survival outcomes in locally advanced breast cancer. Curr Oncol, 31(10): 6007-6016. [ DOI:10.3390/curroncol31100448] 11. McGale P, Dodwell D, Taylor C, Gray R (2018) Neoadjuvant chemother apy for early breast cancer - Author's reply. Lancet Oncol, 19(3): e130. [ DOI:10.1016/S1470-2045(18)30120-7] 12. Cortes J, Haiderali A, Huang M, Pan W, Schmid P, Akers KG, et al. (2023) Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis. BMC Cancer, 23(1): 792. [ DOI:10.1186/s12885-023-11293-4] 13. Miyashita H, Satoi S, Cruz C, Malamud SC (2020) Neo-adjuvant therapy for triple-negative breast cancer: Insights from a network meta-analysis. Breast J, 26(9): 1717-1728. [ DOI:10.1111/tbj.13978] 14. Charfare H, Limongelli S, Purushotham AD (2005) Neoadjuvant chem otherapy in breast cancer. Br J Surg, 92(1): 14-23. [ DOI:10.1002/bjs.4840] 15. Budrukkar AN, Sarin R, Shrivastava SK, Deshpande DD, Dinshaw KA (2007) Cosmesis, late sequelae and local control after breast-conserving therapy: influence of type of tumour bed boost and adju vant chemotherapy. Clin Oncol, 19(8): 596-603. [ DOI:10.1016/j.clon.2007.06.008] 16. Mathew J, Asgeirsson KS, Cheung KL, Chan S, Dahda A, Robertson JF (2009) Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directions. Eur J Surg Oncol, 35(2): 113-22. [ DOI:10.1016/j.ejso.2008.03.015] 17. Tinterri C, Barbieri E, Sagona A, Bottini A, Canavese G, Gentile D (2024) De-Escalation Surgery in cT3-4 Breast Cancer Patients after Neoadju vant Therapy: Predictors of Breast Conservation and Comparison of Long-Term Oncological Outcomes with Mastectomy. Cancers (Basel), 16(6): 1169. [ DOI:10.3390/cancers16061169] 18. Krug D, Lederer B, Seither F, Nekljudova V, Ataseven B, Blohmer JU, et al. (2019) Post-mastectomy radiotherapy after neoadjuvant chemo therapy in breast cancer: a pooled retrospective analysis of three pro spective randomized trials. Ann Surg Oncol, 26(12): 3892-3901. [ DOI:10.1245/s10434-019-07635-x] 19. Chakravarthy AB (2017) Neoadjuvant chemoradiation in the treatment of locally advanced breast cancer. Int J Radiat Oncol Biol Phys, 99(4): 784-786. [ DOI:10.1016/j.ijrobp.2017.08.002] 20. Gajdos C, Tartter PI, Estabrook A, Gistrak MA, Jaffer S, Bleiweiss IJ (2002) Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. J Surg Oncol, 80(1): 4-11. [ DOI:10.1002/jso.10090] 21. Woodward WA, Fang P, Arriaga L, Gao H, Cohen EN, Reuben JM, et al. (2017) A phase 2 study of capecitabine and concomitant radiation in women with advanced breast cancer. Int J Radiat Oncol Biol Phys, 99(4): 777-783. [ DOI:10.1016/j.ijrobp.2017.04.030] 22. Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, et al. (2003) Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA, 290(4): 465-475. [ DOI:10.1001/jama.290.4.465] 23. van Leeuwen FE, Klokman WJ, Stovall M, Dahler EC, van't Veer MB, Noordijk EM, et al. (2003) Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst, 95(13): 971-980. [ DOI:10.1093/jnci/95.13.971] 24. Chewchuk S, Guo B, Parissenti AM (2017) Alterations in estrogen sig naling pathways upon acquisition of anthracycline resistance in breast tumor cells. PLoS One, 12(2): e0172244. [ DOI:10.1371/journal.pone.0172244] 25. BeLow M and Osipo C (2020) Notch signaling in breast cancer: a role in drug resistance. Cells, 9(10): 2204. [ DOI:10.3390/cells9102204] 26. Arriagada R, Mouriesse H, Sarrazin D, Clark RM, Deboer G (1985) Radi otherapy alone in breast cancer. I. Analysis of tumor parameters, tu mor dose and local control: the experience of the Gustave-Roussy In stitute and the Princess Margaret Hospital. Int J Radiat Oncol Biol Phys, 11(10): 1751-1757. [ DOI:10.1016/0360-3016(85)90027-6] 27. Arriagada R, Mouriesse H, Rezvani A, Sarrazin D, Clark RM, DeBoer G, Bush RS (1993) Radiotherapy alone in breast cancer. Analysis of tumor and lymph node radiation doses and treatment-related complications. The experience of the Gustave-Roussy Institute and the Princess Mar garet Hospital. Radiother Oncol, 27(1): 1-6. [ DOI:10.1016/0167-8140(93)90037-9] 28. Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, Mc Cor mick B, et al. (2013) Lumpectomy plus tamoxifen with or without irra diation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol, 31: 2382-2387. [ DOI:10.1200/JCO.2012.45.2615] 29. Tabár L, Dean PB, Lee Tucker F, Yen AM, Chang RW, Hsu CY, et al. (2022) Breast cancers originating from the major lactiferous ducts and the process of neoductgenesis: Ductal Adenocarcinoma of the Breast, DAB. Oncotarget, 8(24): 39703-39710. [ DOI:10.1016/j.ejrad.2022.110363] 30. Huang L, Chen S, Yang WT, Shao Z (2017) Risk factors of locoregional relapse in locally advanced breast cancer treated with neoadjuvant chemotherapy following mastectomy and radiotherapy. Oncotarget, 8(24): 39703-39710. [ DOI:10.18632/oncotarget.14407] 31. Haussmann J, Budach W, Corradini S, Krug D, Bölke E, Tamaskovics B, et al. (2023) Whole breast irradiation in comparison to endocrine ther apy in early-stage breast cancer-a direct and network meta-analysis of published randomized trials. Cancers, 15(17): 4343. [ DOI:10.3390/cancers15174343]
Send email to the article author
|
